Sponsors (2)
The bill trades extended market incentives and stricter safety parity to encourage botanical drug innovation and investment against higher near‑term prices, potential market concentration, supply and manufacturing risks, and shifted public R&D priorities.
Patients with chronic or age-related conditions may gain new multi‑constituent botanical treatment options if expanded exclusivity and incentives spur development.
Manufacturers, investors, and research developers gain stronger commercial incentives (12 years of market protection and other incentives) that are likely to increase investment in botanical R&D and associated economic activity.
Patients are protected because qualifying botanical drugs would be required to meet the same safety and effectiveness standards as other approved drugs.
Patients, hospitals, and taxpayers may face higher drug prices and reduced access to cheaper generic or alternative products for up to 12 years because of extended exclusivity.
Hospitals and patients may see delayed competition and concentrated market power as exclusivity limits substitution and competition, weakening supply resilience and potentially worsening shortages.
Hospitals, health systems, and patients face higher development costs, supply‑chain risks, and potential product variability because botanical manufacturing and raw‑material variability are complex.
Based on analysis of 3 sections of legislative text.
Provides a 12‑year FDA regulatory exclusivity period blocking referential or generic approvals for qualifying botanical drugs approved from post‑enactment applications.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to provide a period of market exclusivity for botanical drugs, and for other purposes.
Introduced August 27, 2026 by Lauren Boebert · Last progress August 27, 2026
Creates a new 12-year market exclusivity period for certain FDA‑approved botanical drugs, blocking generic or referencing applications that rely on those botanical drugs for 12 years when the approved drug comes from an application submitted after enactment. Directs the FDA to define which products qualify as "botanical drugs" for this exclusivity rule by regulation. The change is meant to increase incentives for development of multi-constituent, multi-target botanical therapies by reducing near-term competition and addressing scientific and manufacturing challenges that have limited approvals under the existing pathway.